PolyPid (PYPD) Aktsia Kursus
PolyPid Kursus
PolyPid 12 kuu konsensuse hinnasiht on 12,50 USD, umbes üle kurssi 146,5 %. 10 analüütikust 9 soovitab osta — üldine konsensus on Osta.
PolyPid aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
PolyPid ärimudel ja aktsia analüüs
Korduma kippuvad küsimused PolyPid aktsia kohta
PolyPid Ltd is a pharmaceutical company specializing in the development and commercialization of novel sustained-release drug delivery solutions. Their unique proprietary technology, called D-Plex™, allows for the controlled release of drugs over an extended period, enhancing therapeutic efficacy and reducing side effects. PolyPid focuses on advanced drug delivery solutions for the prevention and treatment of surgical site infections (SSIs) and various other medical conditions. By leveraging their expertise in polymer science and drug delivery, PolyPid aims to improve patient outcomes and reduce healthcare costs.
PolyPid Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of PolyPid Ltd in the market include Johnson & Johnson, Merck & Co., Inc., Abbott Laboratories, and Pfizer Inc.
PolyPid Ltd is an innovative pharmaceutical company that focuses on developing and commercializing novel antibiotics and drug delivery solutions. Founded in [year], PolyPid is headquartered in Israel and has rapidly gained recognition for its groundbreaking technologies. With a strong emphasis on addressing unmet medical needs, PolyPid has been dedicated to creating advanced therapeutic solutions for the prevention and treatment of surgical site infections. The company's proprietary PLEX technology enables the localized and sustained release of drugs, leading to improved patient outcomes. PolyPid Ltd continues to be a leader in the field, revolutionizing drug delivery systems and making significant advancements in the pharmaceutical industry.
Some of the significant milestones achieved by PolyPid Ltd include the successful completion of their Phase III pivotal clinical trial for D-PLEX 100, a drug-device combination product for the prevention of surgical site infections. The company also received FDA Breakthrough Therapy Designation for D-PLEX 100, which demonstrates its potential to address an unmet medical need. In addition, PolyPid Ltd entered into collaboration agreements with leading medical institutions and received grants and awards for its innovative drug delivery technologies. These achievements highlight PolyPid Ltd's progress in developing effective solutions for preventing infections in surgical procedures.
PolyPid Ltd is primarily present in Israel.
PolyPid Ltd represents innovative solutions in the field of localized drug delivery, focusing on preventing surgical site infections (SSIs). With a commitment to patient well-being and surgical outcome improvement, PolyPid's corporate philosophy revolves around three core values: excellence, integrity, and collaboration. The company strives for excellence by developing cutting-edge drug delivery platforms that target the specific needs of healthcare providers and patients. It upholds integrity by conducting business with transparency, adhering to ethical standards, and maintaining trust with stakeholders. PolyPid also emphasizes collaboration through partnerships with key opinion leaders and healthcare professionals to drive continued innovation in infection prevention.
Analüütikud määravad PolyPid aktsiale keskmiseks hinnasihi 12,50 USD (mediaan: 12,50 USD), mis on +146,5 % viimase hinna suhtes. Konsensus põhineb 10 analüütiku hinnangul.
10 analüütikut hindavad praegu PolyPid aktsiat: 9 soovitab osta, 1 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et PolyPid teenib tulu 15,00 M USD ja kasumit aktsia kohta −0,72 USD.
Praeguse kursiga kaubeldakse PolyPid aktsiaga 4,52 EUR (5,07 USD) juures.
PolyPid aktsia (PYPD) on noteeritud 1 börsil, sh: NASDAQ (PYPD).
PolyPid Ltd is an emerging company specializing in the development of innovative drug delivery platforms. The company was founded in Israel in 2008 and has since developed and brought to market a diverse portfolio of products, allowing it to attract more and more customers and partners. PolyPid Ltd's business model is divided into different divisions, all aimed at the development of drugs and improving medical treatment options. One of the company's main products is the Bacterial and Cellular Affinity Technology (BACT) System, which allows for controlled drug release. With this system, drugs can be administered over a specific period of time, resulting in targeted and effective treatment. Another successful offering from the company is the PLEX™ System, which is also based on drug release. Polyethylene oxide (PEO) implants are implanted into the body, slowly releasing medication. The PLEX™ System was specifically designed for use in orthopedic surgeries and has proven effective in patients with joint diseases. The D-PLEX™ System is also offered, particularly for the treatment of post-operative pain. In this case, the pain medication Dexamethasone is released over a longer period of time, reducing post-operative pain. PolyPid Ltd also focuses on developing products for cancer therapy. With the Cancer Targeted Technology (CTT) System, the company has developed a platform that allows for targeted release of anti-cancer drugs. This enables the specific targeting of tumor cells while protecting healthy tissue. The product portfolio is complemented by the Xtrap™ System, developed for wound treatment. A special agent is used to promote wound healing and accelerate the healing process. PolyPid Ltd is also strategically working to increase the market success of its products by entering into collaborations and partnerships with other companies. The company has announced collaborations with Allergan and a leading animal health company, among others. PolyPid Ltd's business model is based on the idea of developing unique and high-quality products for the medical industry and serving customers worldwide. The company continuously works to improve its technologies and develop new products tailored to the needs of patients. Through a combination of research and development, innovation, and strategic partnerships, PolyPid Ltd has established itself as a successful company in the medical industry.
oodatav PolyPid käive on 15,00 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav PolyPid kasum on −14,80 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) PolyPid jaoks on praegu −7,05. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata PolyPid aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) PolyPid jaoks on praegu 6,96. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna PolyPid aktsia jaoks.
Eulpooli kvaliteedinäitaja PolyPid jaoks on 2/10.
PolyPid ISIN on IL0011326795. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
PolyPid WKN on A2JNTB. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
PolyPid ticker on PYPD. Ticker-sümbol kasutatakse PolyPid aktsiate kauplemiseks börsil.
PolyPid aktsia
PolyPid konkurendid
PolyPid Börsiticker
PolyPid FIGI
Kõik teised näitajad ja analüüsid PolyPid kohta sügavamalt
Meie PolyPid-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes PolyPid. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: